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http:WHAT THIS PAPER ADDS
This study will guide surgeons in the evaluation and treatment of patients with aortic involvement of Behçet’s
Disease before endovascular surgery.Objectives: Aortic aneurysm is a serious problem in Behçet’s disease, but open surgical therapy carries the risk of
recurrent pseudoaneurysm. Here the outcomes of endovascular repair and adjunctive immunosuppressive
therapy for aortic disease in Behçet’s disease are presented.
Materials: This was a retrospective study. Between 2002 and 2012, nine patients with Behçet’s disease (8 male,
median age 41 years, range 33e60 years) were treated by endovascular stent grafting for abdominal or thoraco-
abdominal aortic pseudoaneurysm.
Methods: Computed tomography angiography revealed infrarenal pseudoaneurysm in six (66.6%) patients and
suprarenal pseudoaneurysm in three (33.3%). Patients received immunosuppressive therapy with oral
prednisolone (60 mg/day) and cyclophosphamide (200 mg/day) for 2 weeks or more before the procedure, and
intravenous hydrocortisone (200 mg/day) combined with cyclophosphamide (200 mg/day) for 3 days after the
procedure. Thereafter, oral immunosuppressive therapy was continued for 2 years.
Results: A straight tube graft was implanted in seven patients and a bifurcated graft in two patients. Two stage
procedures (debranching before endovascular therapy) were performed in three patients for thoraco-abdominal
aortic pseudoaneurysms. Stent grafting was successful in all patients, without any peri-operative complications.
However, two patients needed abdominal exploration later: one for seroma around the graft and the other for a
ﬁstula between the duodenum and the graft. No recurrence of aneurysm was observed during a mean follow up
of 40  16 months. One patient died in the 15th month from a non-vascular cause.
Conclusions: Endovascular stent graft implantation and adjunctive immunosuppressive therapy seems to be safe
and effective in the treatment of aortic involvement in Behçet’s disease, but this approach needs further evaluation.
 2015 European Society for Vascular Surgery. Published by Elsevier Ltd. All rights reserved.
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In 1937, Turkish dermatologist Hulusi Behçet ﬁrst described
the disease that bears his name. The disease consists of
recurrent ulcers in oral and genital mucosae and relapsing
uveitis.1,2 Although the cause of Behçet’s disease is un-
known, the disease is a multisystem inﬂammatory disorder
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//dx.doi.org/10.1016/j.ejvs.2015.07.011cardiovascular, musculoskeletal, and urogenital involve-
ment.2,3 Vasculitis is the predominant histopathological
lesion, which may affect blood vessels of any size.4 Vascular
lesions occur in 25e30% of Behçet’s disease patients, the
most frequent being deep venous thrombosis, especially in
the lower extremities.4e7 Usually, both arteries and veins
are involved; pure arterial involvement is rare. Aortic lesions
such as aneurysms, occlusions, and pseudoaneurysms can
cause life threatening complications8 and increase mortality
and morbidity rates.3
The abdominal aorta is the most common site of arterial
involvement in Behçet’s disease, followed by the pulmo-
nary, femoral, popliteal, and carotid arteries in that order.
Conventional open surgery is the most frequently used
treatment for the arterial lesions in Behçet’s disease pa-
tients.9 Pseudoaneurysm at the site of the anastomosis is
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Recent studies have shown that endovascular stent grafting
may offer an alternative treatment for arterial aneurysms in
Behçet’s disease.4,10e15 Also, endovascular treatment
combined with immunosuppressive therapy has been re-
ported to be associated with better post-operative results
and lower recurrence rates than open repair.4
In this study, the outcome of endovascular stent graft
implantation and adjunctive immunosuppressive therapy
for the treatment of abdominal or thoraco-abdominal aortic
aneurysms in Behçet’s disease has been evaluated.MATERIALS AND METHODS
Between 2002 and 2012, nine consecutive patients (8
male), with a median age of 41 (33e60) years, with Beh-
çet’s disease underwent endovascular stent grafting either
for abdominal or thoraco-abdominal aortic aneurysm. All
patients had been referred to the department from the
rheumatology clinic with a diagnosis of Behçet’s disease.
The diagnosis was made according to the criteria of the
International Study Group of Behçet’s Disease.2 Four
(44.5%) patients were asymptomatic; three of them were
followed by the rheumatology department and one was
diagnosed incidentally (during abdominal ultrasonography);
ﬁve (55.5%) had back pain.
Aortic aneurysms were imaged with thoraco-abdominal
computed tomography angiography (CTA). The specializedFigure 1. (A) Patient with infrarenal abdominal aortic pseudoaneurys
tomography (CT) of the pseudoaneurysm, early after the endovascular
the pseudoaneurysm.endovascular team evaluated all CTA images before the
procedure to measure the diameter of the aneurysm and
select the appropriate stent graft (Fig. 1). In this cohort, six
patients (66.6%) had infrarenal abdominal aortic pseudoa-
neurysm and three (33.3%) had suprarenal pseudoaneur-
ysm (Table 1). Vascular involvement in Behçet’s Disease
may occur in multiple sites. Interestingly, no co-existing
lesions, such as peripheral pseudoaneurysm or occlusion
(femoral, popliteal, subclavian, etc.), were shown in the CTA
images. The CTA images showed that all the aortic pathol-
ogies were saccular pseudoaneurysms. The aneurysm sacs
were irregular and ﬁlled with thrombus without any calci-
ﬁcation, which differs from atherosclerotic aneurysms. The
mean diameters were 5.6 cm and 6 cm for infrarenal and
suprarenal pseudoaneurysms respectively. In spite of the
contained rupture, patients were clinically stable before
intervention. For follow up, CTA was performed in all pa-
tients post-operatively during the ﬁrst, sixth, and 12th
month, and yearly thereafter (Fig. 2). The same radiologist
evaluated all the CTA scans.
Before endovascular procedures, full blood count and
biochemical markers were measured in all patients. Eight of
the nine patients received immunosuppressive therapy,
consisting of oral prednisolone at least 2 weeks before
(60 mg/day) and cyclophosphamide 3 days (200 mg/day)
before the procedure. All patients were monitored to con-
trol hemodynamics for risk of rupture. Biochemical tests
were performed daily to check possible side effects ofm. (B) Angiographic view of the pseudoaneurysm. (C) Computed
procedure. (D) CT scan at the18th month showing the regression of
Table 1. Demographic and operative patient data.
Age Sex Aneurysm location Type of
stent graft
Graft size (diameter/length) Additional procedure Result/Follow up
Patient 1 40 M Infrarenal AAA Tube 28 mm/8 cm None Death/12 monthsa
Patient 2 39 M Type 4 TAAA Y graft 26 mm/10 cm Visceral debranching Alive/48 months
Patient 3 41 M Infrarenal AAA Tube 22 mm/8 cm None Alive/52 months
Patient 4 60 M Infrarenal AAA Y graft 23 cm,
12e14 mm (the body)
12e10 mm (counterside)
None Alive/60 months
Patient 5 41 M Type 4 TAAA Tube 34 mm/15 cm Visceral debranching Alive/55 months
Patient 6 59 F Type 4 TAAA Tube 34 mm/20 cm Visceral debranching Alive/39 months
Patient 7 46 M Infrarenal AAA Tube 22 mm/10 cm None Alive/36months
Patient 8 33 M Infrarenal AAA Tube 24 mm/10 cm None Alive/34 months
Patient 9 45 M Infrarenal AAA Tube 24 mm/10 cm None Alive/24 months
AAA ¼ abdominal aortic aneurysm; F ¼ female; HA ¼ hepatic artery; LRA ¼ left renal artery; M ¼ male; RRA ¼ right renal artery;
SMA ¼ superior mesenteric artery; TAAA ¼ thoraco-abdominal aortic aneurysm; TC ¼ Coeliac trunk.
a Death due to non-vascular cause.
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was implanted when the inﬂammatory markers (erythro-
cyte sedimentation rate and C-reactive protein) had
declined to the normal range. In an asymptomatic patient
whose aneurysm was diagnosed incidentally during uro-
genital examination, immunosuppressive therapy was ﬁrst
started after endovascular treatment with the administra-
tion of intravenous hydrocortisone (200 mg/day) andFigure 2. (A) Patient with suprarenal abdominal aortic pseudoaneur
endovascular procedure. (C) Intra-operative view of visceral grafts. (D) T
after graft implantation. SMA ¼ superior mesenteric artery.cyclophosphamide (200 mg/day) for 3 days, based on the
erythrocyte sedimentation rate and C-reactive protein
values; then oral medication was started as the mainte-
nance treatment.
For all patients, the post-operative immunosuppressive
drug dosages were adjusted by a rheumatologist, on the
basis of the patient’s symptoms and the erythrocyte sedi-
mentation rate.ysm. (B) Control angiogram of the visceral bypass grafts before
hree dimensional reconstruction image of the aneurysm 4 months
Table 2. Target vessels and graft properties used for debranching.
Patient Target vessel Graft size and type
Patient
2
Hepatic artery 6 mm, ringed PTFE
Left renal artery 5 mm, ringed PTFE
Superior mesenteric
artery
8 mm, ringed PTFE
Right renal artery 6 mm to 5 cm, Viabahn
graft
Patient
5
Left renal artery 5 mm, ringed PTFE
Superior mesenteric
artery
8 mm, ringed PTFE
Right renal artery 5 mm, ringed PTFE
Patient
6
Coeliac trunk 8 mm, Ringed PTFE
Left renal artery 6 mm, Ringed PTFE
Superior mesenteric
artery
8 mm, Ringed PTFE
Right renal artery 6 mm, Ringed PTFE
PTFE ¼ polytetraﬂuoroethylene.
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All procedures were performed successfully without peri-
operative complications, and no patient required conver-
sion to open repair. A tube stent graft was implanted in ﬁve
patients with infrarenal aneurysms and in two patients with
suprarenal aneurysms. Bifurcated stent grafts were
implanted in one patient in each anatomical location.
Aortography was performed at the end of the procedures to
verify the appropriate placement of the stent graft. No
endoleaks were documented. Upon completion of the 3 day
medical treatment therapy the patients were discharged.
Two stage procedures were used in three patients who
had ruptured type 4 thoraco-abdominal aortic aneurysms.
The visceral debranching procedure was performed ﬁrst
followed by the endovascular procedure, to prevent intes-
tinal and renal ischemia. A single main graft, as a source of
inﬂow, was anastomosed to the common iliac artery (Fig. 2).
Endograft implantation was performed on the same day
after the completion of the visceral bypass. Information
about the bypass grafts is shown in Table 2.
Endovascular stent grafting was performed under spinal
or general anesthesia, depending on the patient’s condition.
Surgical exploration of the femoral artery was done on one
side and percutaneous puncture on the opposite side.
Surgical arteriotomies were closed with 6/0 polypropylene
sutures. High pressure compression was applied to the
percutaneous puncture site for 8 hours after the procedure.
There were no procedure related complications.
The mean follow up was 40  16 months. One patient
died during the 15th month from a non-vascular cause. The
patients’ survival rate was 100% and 88% at the ﬁrst and
second years, respectively. The event free survival rate
during the ﬁrst year was 77%, and for the entire follow up
period was 67%. Immunosuppressive therapy was
continued for 2 years, without any signiﬁcant side effects.
Two patients were lost to follow up. Physical examination
and blood tests were done for all patients at each follow upvisit on a routine basis; CTA was performed to conﬁrm stent
graft patency, leakage, and pseudoaneurysm, 1, 6, and 12
months after the operation and every year subsequently.
No pseudoaneurysms or graft occlusions were encountered.
The diameter of the aneurysm sac had decreased in all
patients at the sixth month (Fig. 1). Patient 5 required
abdominal exploration 15 months after the operation for a
suspected abscess, which revealed seroma around the
abdominal debranching grafts; no additional procedures
were needed. Patient 6 experienced back pain, high fever,
and weight loss after 24 months. CTA showed a ﬁstula
between the duodenum and the vascular graft, with air
bubbles around the bypass graft to the superior mesenteric
artery. Laparotomy revealed a ﬁstula. The duodenum was
resected, the abscess was drained, and the visceral graft
was replaced and covered with omentum to prevent re-
infection.DISCUSSION
In this study, endovascular stent graft implantation com-
bined with immunosuppressive therapy for the treatment
of aortic pseudoaneurysm in Behçet’s disease was evalu-
ated. The major ﬁnding was that the operation was per-
formed successfully in most patients, with low morbidity
and mortality rates. Indeed, no peri-operative complications
occurred, and the only death was unrelated to the
operation.
The expression of vasculitis due to Behçet’s disease may
be in many clinical forms. Although, aneurysm and pseu-
doaneurysm are mostly seen in the arterial system,
thrombosis occurs in the venous system. Arterial aneurysms
are the most serious ones because of the inherited high risk
of rupture.11 The abdominal aorta is the most common
location of aneurysms in Behçet’s disease, followed by the
pulmonary and femoral arteries.16e18 Until recently, open
surgical therapy was the only treatment option for these
aneurysms. Unfortunately, that approach often resulted in
the development of pseudoaneurysm or leakage at the
anastomotic sites, or graft occlusions during the post-
operative period.9,12,13,19,20 Schneider et al. reported a
case with early graft occlusion and late pseudoaneurysm
formation after an aneurysmectomy and prosthetic revas-
cularization for abdominal aortic and left femoral artery
aneurysms.19 Hosaka et al. reported a study of 10 patients
with Behçet’s Disease who underwent open surgery for
arterial involvement. They observed ﬁve graft occlusions
and ﬁve anastomotic pseudoaneurysms during the post-
operative follow up period.21 Several studies have shown
similar results for graft occlusions after peripheral bypass
surgery.18,21,22 The pathological mechanism of post-
operative graft occlusion is unclear. Some authors believe
that the systemic pro-coagulative state and inﬂammatory
activity in patients with Behçet’s disease might lead to wall
thickening and occlusions in both native arteries and
implanted grafts.21
Anastomotic pseudoaneurysm is another life threatening
complication, occurring after open repair of Behçet’s disease.
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the main reason for this complication. There are various
options to reduce the high recurrence rate of anastomotic
pseudoaneurysm. Kalko et al.23 treated 16 patients and 18
aneurysms using an open surgical technique. They suggest
using immunosuppressive therapy (glucocorticoid and
cyclophosphamide) before surgery if the patient is hemody-
namically stable and performing the anastomosis on disease
free arterial walls. Apart from urgent patients, Kalko et al.23
preferred to wait until the inﬂammatory markers dimin-
ished, otherwise immunosuppressive therapywas given after
surgery. Tüzün et al.22 reported eight peripheral aneurysms
treated by ligation after conﬁrming stump pressure. Kwon
et al.11 used prosthetic wrapping on the proximal anasto-
motic site in all cases of graft interposition and omental
wrapping for infrarenal aortic aneurysms to prevent recur-
rence. In addition, they performed a patch closure technique,
but the patch closure technique was associated with a high
aneurysm recurrence rate (62.5%).11 Post-operative cortico-
steroid therapy and systemic immunosuppression have been
suggested as efﬁcacious preventive medication for anasto-
motic pseudoaneurysm.18,22 Hosaka et al.21 reported long-
term results after surgical treatment of arterial lesions in
Behçet’s disease.They reported no arterial relapse in patients
treated with corticosteroid after surgery. Moreover, they
reported that ﬁve of eight patients who did not receive
corticosteroids had experienced new aneurysm formation.21
In 1998, Vasseur et al.14 performed the ﬁrst endovascular
treatment in Behçet’s disease to treat aorto-iliac aneu-
rysms. After that experience, other investigators tried this
less invasive surgical alternative. Liu et al.10 reported 10
patients with pseudoaneurysm due to Behçet’s disease who
underwent endoluminal stent graft implantation; they
experienced no peri-operative complications. However, the
authors lost one patient 8 months after the procedure due
to rupture of a recurrent aneurysm. Park et al.15 reported
that one of seven patients developed recurrence at the
distal landing zone of the stent graft. Thus, aneurysms can
recur in Behçet’s disease patients even after endovascular
grafting. It has been suggested that recurrence of aneu-
rysms after stent graft implantation might occur because of
chronic tissue inﬂammation at the edge of the stent graft.15
Because of the high rate of recurrence of aneurysms
after vascular operation in Behçet’s disease patients, most
vascular surgeons today believe that surgical treatment
without additional immunosuppressive therapy is not
adequate.21 Aneurysm formation in Behçet’s disease is
different from that of degenerative aneurysms; the main
problem in the aortic aneurysms of Behçet’s disease is that
active inﬂammation can destroy the aortic wall. Predictably,
any vascular operation on the aneurysms can cause new
weak areas at the anastomotic sites and lead to the
development of new aneurysms. Ozeren et al.16 proposed
that fewer invasive techniques combined with medical
therapy would give better results than open surgery.
Nitecki et al.4 compared open surgery and endovascular
repair techniques for abdominal aortic aneurysm in Beh-
çet’s disease. They reported high recurrence withpseudoaneurysm formation in the open surgery group and
none in those treated endovascularly.4 Endovascular repair
of aortic aneurysms was preferred in the current study,
combined with immunosuppressive therapy with the
intention of reducing the severity of vascular inﬂammation
and thus decreasing the likelihood of aneurysm recurrence.
Recurrent aneurysms were not observed. Although solid
evidence supporting the superiority of the combined
endovascular and medical approach for aortic aneurysms in
Behçet’s disease is lacking, it is believed that all such pa-
tients should be given immunosuppressive therapy before
and after stent graft implantation. The total endovascular
approach with a fenestrated endograft may be a better
option in patients with thoraco-abdominal aneurysm to
minimize surgical risk.
On the basis of limited experience, endovascular stent
graft implantation combined with immunosuppressive
therapy appears to be an efﬁcacious treatment for aortic
aneurysms in Behçet’s disease. The endovascular approach
is less invasive than open surgery, and immunosuppressive
therapy may help to prevent recurrence of aneurysms.
Further, prospective studies on a larger scale are warranted.CONFLICT OF INTEREST
None.FUNDING
None.REFERENCES
1 Behçet H. Über rezidivierende, aphtöse, durch ein virus ver-
urschate Geshwüre am Mund, am Auge und an den Ganitalien.
Dermatol Woschenschr 1937;105:1152e7.
2 Wechsler B, Davatchi F, Mizushima Y, Hamza M, Dilsen N,
Kansu E, et al. Evaluation of diagnostic (‘Classiﬁcation’) criteria
in Behçet’s disease e towards internationally agreed criteria.
The International Study Group for Behçet’s disease. Br J
Rheumatol 1992;31(5):299e308.
3 Ko GY, Byun JY, Choi BG, Cho SH. The vascular manifestations of
Behçet’s disease: angiographic and CT ﬁndings. Br J Radiol
2000;73(876):1270e4.
4 Nitecki SS, Ofer A, Karram T, Schwartz H, Egel A, Hoffman A.
Abdominal aortic aneurysm in Behçet’s disease: new treatment
options for an old and challenging problem. Isr Med Assoc J
2004;6:152e5.
5 Düzgün N, Ates¸ A, Aydintug OT, Demir O, Olmez U. Charac-
teristics of vascular involvement in Behçet’s disease. Scand J
Rheumatol 2006;35(1):65e8.
6 Hassikou H, Bono W, Bahiri R, Abir S, Benomar M, Hassouni NH.
Vascular involvement in Behçet’s disease. Two case reports.
Joint Bone Spine 2002;69(4):416e8.
7 Tascilar K, Melikoglu M, Ugurlu S, Sut N, Caglar E, Yazici H.
Vascular involvement in Behçet’s syndrome: a retrospective
analysis of associations and the time course. Rheumatology
2014;53:2018e22.
8 Fei Y, Li X, Lin S, Song X, Wu Q, Zhu Y, et al. Major vascular
involvement in Behçet’s disease: a retrospective study of 796
patients. Clin Rheumatol 2013;32(6):845e52.
598 O. Balcioglu et al.9 Koksoy C, Gyedu A, Alacayir I, Bengisun U, Uncu H, Anadol H.
Surgical treatment of peripheral aneurysms in patients with
Behçet’s disease. Eur J Vasc Endovasc Surg 2011;42(4):525e30.
10 Liu CW, Ye W, Liu B, Zeng R, Wu W, Dake MD. Endovascular
treatment of aortic pseudoaneurysm in Behçet’s disease.
J Vasc Surg 2009;50(5):1025e30.
11 Kwon TW, Park SJ, Kim HK, Yoon HK, Kim GE, Yu B. Surgical
treatment result of abdominal aortic aneurysm in Behçet’s
disease. Eur J Vasc Endovasc Surg 2008;35(2):173e80.
12 Kwon KB, Shim WH, Yoon YS, Kwon Lee B, Choi D, Jang Y, et al.
Endovascular therapy combined with immunosuppressive
treatment for pseudoaneurysms in patients with Behçet’s
disease. J Endovasc Ther 2003;10(1):75e80.
13 Ohira S, Masuda S, Matsushita T. Nine-year experience of
recurrent anastomotic pseudoaneurysms after thoraco-
abdominal aneurysm graft replacement in a patient with
Behcet disease. Heart Lung Circ 2014;23:e210e3.
14 Vasseur MA, Haulon S, Beregi JP, Le Tourneau T, Prat A,
Warembourgh H. Endovascular treatment of abdominal aneu-
rysmal aortitis in Behçet’s disease. J Vasc Surg 1998;27:974e6.
15 Park JH, Chung JW, Joh JH, Song SY, Shin SJ, Chung KS, et al.
Aortic and arterial aneurysms in Behçet’s disease: management
with stent grafts e initial experience. Radiology 2001;220:
745e50.16 Ozeren M, Mavioglu I, Dogan OV, Yucel E. Reoperation results
of arterial involvement of Behçet’s disease. Eur J Vasc Endovasc
Surg 2000;20:512e6.
17 Hamza M. Large artery involvement in Behçet’s disease.
J Rheumatol 1987;14(3):554e9.
18 Lê Thi Huong D, Wechsler B, Papo T, Piette JC, Bletry O,
Vitoux JM, et al. Arterial lesions in Behçet’s disease. A study in
25 patients. J Rheumatol 1995;22(11):2103e13.
19 Schneider F, Gouny P, Van Laere O, Duedal V, Nussaume O.
Vascular complications after surgical repair of aneurysms in
Behçet’s disease. J Cardiovasc Surg (Torino) 2002;43(4):501e5.
20 Tohmé A, Aoun N, El-Rassi B, Ghayad E. Vascular manifestations
of Behçet’s disease eighteen cases among 140 patients. Joint
Bone Spine 2003;70:384e9.
21 Hosaka A, Miyata T, Shigematsu H, Shigematsu K, Okamoto H,
Ishii S, et al. Long-term out come after surgical treatment of
arterial lesions in Behçet disease. J Vasc Surg 2005:42116e21.
22 Tüzün H, Bes¸irli K, Sayin A, Vural FS, Hamuryudan V, Hizli N,
et al. Management of aneurysms in Behcet’s syndrome: an
analysis of 24 patients. Surgery 1997;121:150e6.
23 Kalko Y, Basaran M, Aydin U, Kafa U, Basaranoglu G, Yasar T. The
surgical treatment of arterial aneurysms in Behçet’s disease; a
report of 16 patients. J Vasc Surg 2005;42:673e7.
